icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir
  Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
C. Thorne1, G. Favarato1, H. Peters1, A. Soriano-Arandes2, M. Floridia3, A. Colbers4, T. Goetghebuer5, L. Ragone6, K. Aebi-Popp7, M. Sovric8, D. Burger4, A. Pozniak9, C. Giaquinto10, V. Vannappagari6
1UCL Great Ormond Street Institute of Child Health, London, UK; 2. Hospital UniversitariValld'Hebron, Barcelona, Spain; 3. Istituto Superiore di Sanita, Rome, Italy; 4. RadboudUniversity Medical Centre, Nijmegen, the Netherlands; 5. Hospital St Pierre, Belgium; 6. ViiVHealthcare; 7. Bern University Hospital, Switzerland; 8. Munich University Hospital, Germany; 9. Chelsea & Westminster Hospital, London, UK; 10. PENTA Foundation, Padua, Italy
IAS: Dolutegravir Use During Pregnancy and Birth Outcomes: Data From the Antiretroviral Pregnancy Registry (APR) - (08/02/17)